Enter the baseline scan first, then each follow-up. The latest row is compared with baseline (ESC 2022 echo criteria) and with the previous scan.
| Date | 2D EF % | Contrast EF % | 3D EF % | GLS % | TAPSE mm | Sβ² cm/s | FAC % |
|---|
Pink: 2D EF, with triangles where contrast EF was used; purple: 3D EF (left axis) with 50% and 40% thresholds. Blue: GLS magnitude (right axis); the dotted blue line marks a 15% relative fall from the baseline GLS.
TAPSE (mm) and FAC (%) on the left axis, Sβ² (cm/s) on the right. Dashed lines mark the abnormal cut-offs: TAPSE 17 mm, Sβ² 9 cm/s and FAC 30% (male) or 35% (female) once sex is selected.
BSE LVEF groups: normal β₯55%, borderline low 50β54%, impaired 36β49%, severely impaired β€35%. The CTRCD grade uses the separate ESC 2022 thresholds of 50% and 40%.
A relative fall <8% is unlikely to be meaningful; 8β15% is a grey zone that deserves a repeat; >15% is abnormal (ASE/EACVI; ESC 2022).
DICOM saves the LV and RV trends as one greyscale image (Secondary Capture) to upload to your echo or PACS system. PDF saves the scan table and both trends on an A4 page for printing. Both use a white background with line patterns that read in black and white. Files are built in your browser; nothing is sent anywhere.
Echo is the first-line test before, during and after cardiotoxic cancer therapy. Every follow-up is judged against the patient's own pre-treatment baseline, so measurement consistency matters as much as the numbers.
| Grade | Echo definition | |
|---|---|---|
| Severe | New LVEF reduction to <40% | |
| Moderate | New LVEF fall by β₯10 points to 40β49%, or a fall of <10 points to 40β49% with a relative GLS fall >15% | |
| Mild | LVEF β₯50% with a new relative GLS fall >15% |
CTRCD = cancer therapy-related cardiac dysfunction. The full ESC definition also counts a new biomarker rise and grades symptomatic CTRCD clinically; this page uses the imaging criteria only.
Approximate minimal detectable change between two scans. GLS is more reproducible than 2D LVEF, but only on the same vendor and software.
| GLS | Interpretation |
|---|---|
| More negative than β β18% | Normal for most vendors |
| β16% to β18% | Borderline |
| Less negative than β16% | Likely abnormal |
| Relative fall <8% / 8β15% / >15% | Noise / grey zone / abnormal |
| Measure | Abnormal |
|---|---|
| LVEF (BSE) | 50β54% borderline low, 36β49% impaired, β€35% severely impaired |
| TAPSE | <17 mm |
| RV Sβ² | <9 cm/s |
| RV FAC | <30% male, <35% female |
A short guide to the main cardiotoxic treatments. Baseline risk (HFA-ICOS) is set by the cardio-oncology team and decides how often to scan.
Effect: dose-dependent myocyte injury, mostly in the first year; often subclinical first (GLS before LVEF).
Effect: LV dysfunction that is usually reversible; risk higher after anthracyclines.
Effect: myocarditis (rare, early, can be fatal), pericarditis, arrhythmia.
Effect: hypertension and afterload-driven LV dysfunction.
Effect: late valve disease, pericardial disease, CAD and restrictive physiology, years after treatment.